全部 |
  • 全部
  • 题名
  • 关键词
  • NSTL主题词
  • 摘要
  • 论文-出处
  • 论文-作者
  • 论文-机构
  • 论文-DOI
  • 期刊-出版者
  • 期刊-出版地
  • 期刊-主编
  • ISSN
  • EISSN
  • ISBN
  • EISBN
检索 搜索期刊 二次检索 AI检索
外文文献 中文文献
筛选条件:

1. Lenacapavir for HIV PrEP: Interim Phase III Clinical Data Evaluation NSTL国家科技图书文献中心

Blackwell, Christoph... |  Armstrong, Frances... -  《The journal for nurse practitioners》 - 2025,21(4) - 105360~105360 - 共5页

摘要:) for HIV that is currently undergoing Phase III |  Phase III clinical trials. Lenacapavir is being lauded | Lenacapavir is an antiretroviral medication |  injected every 6 months as pre-exposure prophylaxis (PrEP |  clinical trials worldwide. Interim data suggest
关键词: lenacapavir |  Phase III clinical trials |  pre-exposure prophylaxis (PrEP) for HIV

2. A randomized phase III study evaluating dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in patients with breast cancer NSTL国家科技图书文献中心

Sayaka,Kuba |  Sakiko,Soutome... -  《Japanese journal of clinical oncology.》 - 2025,55(2) - 172~175 - 共6页

摘要:, randomized, open-label, controlled phase III trial aims to | Abstract Stomatitis, which is a common side |  effect of chemotherapy, currently lacks a standardized |  approach for its prevention. Therefore, this multicenter |  assess the efficacy and safety of a dexamethasone-based
关键词: stomatitis |  chemotherapy |  dexamethasone mouthwash |  randomized controlled phase III trial

3. STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma NSTL国家科技图书文献中心

Pal, Sumanta K. |  Powles, Thomas... -  《Future oncology》 - 2025,21(6/7) - 787~794 - 共8页

摘要: treatment strategy, but well-designed, phase III |  with ICIs. STELLAR-304 is a phase III trial | , STELLAR-304 is the first phase III study assessing a TKI | Management of advanced non-clear cell renal |  cell carcinoma (nccRCC) is challenging due to disease
关键词: Zanzalintinib |  XL092 |  nivolumab |  sunitinib |  non-clear cell renal cell carcinoma |  tyrosine kinase inhibitor |  immune checkpoint inhibitor |  phase III

4. Avelumab D axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial NSTL国家科技图书文献中心

Choueiri, T. K. |  Penkov, K.... -  《Annals of oncology》 - 2025,36(4) - 387~392 - 共6页

摘要:Background: In the phase III JAVELIN Renal 101 |  combination treatment from a phase III trial in aRCC. OS |  trial (NCT02684006), first-line treatment with |  avelumab + axitinib resulted in significantly longer |  progression-free survival (PFS) and a higher objective
关键词: avelumab |  axitinib |  sunitinib |  phase III |  advanced renal cell carcinoma

5. The Data Acquisition System for Phase-III of the BeEST Experiment NSTL国家科技图书文献中心

Bray, C. |  Fretwell, S.... -  《Journal of Low Temperature Physics》 - 2025,218(1/2) - 74~82 - 共9页 - 被引量:1

摘要:) detectors. For Phase-III of the experiment, we constructed | The BeEST experiment is a precision laboratory |  search for physics beyond the standard model that |  measures the electron capture decay of 7documentclass | [12pt]{minimal} usepackage{amsmath} usepackage{wasysym
关键词: Superconducting tunnel junctions (STJs) |  Data acquisition systems (DAQs) |  Linearity |  Timing jitter |  BeEST experiment

6. Evaluation of the safety and efficacy of biosimilar recombinant growth hormone in children with growth hormone deficiency: non-inferiority, randomized, parallel, multicentric and Phase III trial NSTL国家科技图书文献中心

Zaeri, Hossein |  Omidvar, Shahriar... -  《Expert opinion on drug safety》 - 2025,24(1) - 111~119 - 共9页

摘要:ObjectivesThis study is designed in order to |  compare the efficacy and safety of recombinant human |  growth hormone (rhGH) with the reference |  brand.MethodsAccording to the inclusion criteria, 85 people in 13 |  Iranian centers were randomly selected to receive
关键词: Human growth hormone |  growth hormone deficiency |  biosimilar |  Phase III |  efficacy |  safety

7. Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial NSTL国家科技图书文献中心

Powles, T. |  Tagawa, S.... -  《Annals of oncology》 - 2025,36(5) - 561~571 - 共11页 - 被引量:2

摘要: of the global open-label randomized phase III |  efficacy and manageable toxicity in the phase II TROPHY-U | Background: Sacituzumab govitecan (SG), a Trop | -2-directed antibody-drug conjugate, demonstrated | -01 study in pretreated advanced urothelial
关键词: antibody-drug conjugate |  bladder cancer |  metastatic urothelial carcinoma |  sacituzumab govitecan |  SN-38 |  topoisomerase I inhibitor

8. Effect of extending the period from oral administration of 5-aminolevulinic acid hydrochloride to photodynamic diagnosis during transurethral resection for non-muscle invasive bladder cancer on diagnostic accuracy and safety: a single-arm multicenter phase III trial NSTL国家科技图书文献中心

Taoka, Rikiya |  Fukuhara, Hideo... -  《International journal of clinical oncology》 - 2025,30(1) - 110~120 - 共11页

摘要:. Therefore, this prospective, single-arm, phase III study | Background In Japan, the authorized period (2 | -4 h) between oral administration of 5 | -aminolevulinic acid hydrochloride (5-ALA) and transurethral |  resection for non-muscle invasive bladder cancer (NMIBC
关键词: Non-muscle invasive bladder cancer |  Photodynamic diagnosis |  5-Aminolevulinic acid |  Multicenter single-arm phase III trial

9. REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC NSTL国家科技图书文献中心

Heymach, John V. |  Yu, Helena A.... -  《Future oncology》 - 2025,21(3/5) - 549~556 - 共8页

摘要: ongoing phase III study evaluating the efficacy and | There remains a significant unmet need for |  effective and tolerable treatments for patients with non | -small cell lung cancer (NSCLC) harboring epidermal |  growth factor receptor (EGFR) exon 20 insertion
关键词: EGFR |  epidermal growth factor receptor |  ex20ins |  exon 20 insertions |  non-small cell lung cancer |  NSCLC |  nonsquamous NSCLC |  zipalertinib

10. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma NSTL国家科技图书文献中心

George Lau |  Ghassan K Abou-Alfa... -  《Journal of Hepatology》 - 2025,82(2) - 258~267 - 共10页 - 被引量:3

摘要:Background & aims: In the global, phase III | : NCT03298451.Impact and implications: The global, phase III |  HIMALAYA study in unresectable hepatocellular carcinoma |  (uHCC), STRIDE (Single Tremelimumab Regular Interval |  Durvalumab) improved overall survival (OS) vs. sorafenib
关键词: Asia; Efficacy; Immune checkpoint inhibitor; Safety; Unresectable hepatocellular carcinoma
检索条件PHASE-III
  • 检索词扩展

NSTL主题词

  • NSTL学科导航